Novartis Signs Xyotax Development Deal With Cell Therapeutics
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis has signed a licensing agreement with Cell Therapeutics that could potentially hasten to market the first gender-specific therapy for the treatment of non-small cell lung cancer